Glaxosmithkline Share News (GSK)

BROKER RATINGS SUMMARY: Goldman Cuts TalkTalk To Neutral From Buy

LONDON MARKET CLOSE: Weak US Services Data Add To Market Gloom

UPDATE 3-GSK dismisses near-term split as new drugs offset falling Advair

* Chances of early consumer unit sale "extraordinarily low" * HIV and new lung drugs lift GSK quarterly sales * Q4 core EPS 18.1p vs consensus 17.9p * Q4 sales 6.29 bln stg vs consensus 6.25 bln (Adds more on options for consumer health business) By Ben Hirschler L

FTSE 100 movers: StanChart leads market lower on Citi note

(ShareCast News) - The FTSE 100 was down again on Wednesday, dropping 78.22 points (1.32%) to 5,843.79 by mid-afternoon. Standard Chartered plunged after Citi lowered its target price on the shares of Asia-focused and commodity-exposed lender. The broker described the lender's valuation at 0.5 times

GSK refuses to be bounced into early consumer unit spin-off

By Ben Hirschler LONDON, Feb 3 (Reuters) - GlaxoSmithKline said on Wednesday it would not be pushed into an early spin-off or sale of its consumer health business, despite speculation the unit could be a target for the likes of Reckitt Benckiser or Procter & Gamble. Britain's biggest

UPDATE: Glaxo To Meet Revenue Target Early As It Reports In-Line 2015

BUZZ-GSK: Reverses course after Q4 results beat

** GlaxoSmithKline's shares up 2 pct, 3rd-largest FTSE 100 gainer, having earlier been down as much as 1.5 pct, after posting Q4 revenue and core EPS ahead of analyst consensus ** Q4 core EPS of 18.1p vs Reuters consensus 17.9p, revenue of 6.286 bln stg vs Reuters consensus of 6.256 bln stg

Glaxo To Meet Revenue Target Early As It Reports In-Line 2015 Results

RPT-New drugs help GSK offset drag of flagging Advair sales

(Repeats with no change in text) LONDON, Feb 3 (Reuters) - Growing demand for new drugs helped GlaxoSmithKline beat forecasts for fourth-quarter earnings by a small margin on Wednesday, offsetting a continued slide in sales of its older Advair respiratory medicine. Sales, in sterling

New drugs help GSK offset drag of flagging Advair sales

LONDON, Feb 3 (Reuters) - Growing demand for new drugs helped GlaxoSmithKline beat forecasts for fourth-quarter earnings by a small margin on Wednesday, offsetting a continued slide in sales of its older Advair respiratory medicine. Sales, in sterling terms, rose 2 percent to 6.29 billion p

LONDON MARKET MIDDAY: Pound Rises After Upbeat UK Service Sector Data

GlaxoSmithKline provides shot in the arm with final results

(ShareCast News) - GlaxoSmithKline posted full year results showing revenues increasing 6% and core earnings per share down 15%, slightly ahead of guidance, and reiterated its confidence that earnings growth would return in 2016 at double-digit levels. The pension fund favourite said it will pay an

WRAPUP 1-Quest for Zika vaccine widens; Africa, Asia deemed vulnerable

* U.N. agency launches Zika global response unit * Sanofi cites Zika's rapid spread in vaccine effort * Zika linked to severe birth defect microcephaly By Stephanie Nebehay and Dominique Vidalon GENEVA/PARIS, Feb 2 (Reuters) - The Zika virus could spread to Africa, Asia an

UPDATE: Glaxo Expands Immunotherapy Collaboration With Adaptimmune

GlaxoSmithKline Expands Immunotherapy Collaboration With Adaptimmune